Panelists discuss how recent insights into delayed resistance mechanisms in EGFR-positive cancers, including the role of combination therapies and improved testing methods, are shaping strategies to better manage and overcome resistance.
Have you learned anything new since like at least EGFR and have you had combinations. That delayed resistance. How about testing and how about impacting resistance?